Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VORthis companyVor Biopharma Inc.	$20.45	-0.19×	-0.79×	0×	0.38×	104.7%	0.0%	0.0%	0.0%	423.6%	-84.6%	-111.3%	-0.02×	0.57×	0×	18.2×	0.0%	3	6.9	3	B
EDITEditas Medicine, Inc.	$2.68	-1.14×	6.67×	4.49×	-0.75×	-308.6%	100.0%	-245.2%	-395.0%	-586.6%	-65.6%	-91.2%	2.81×	0.47×	-16.1×	3.54×	0.0%	3	-8.13	2	C
FATEFate Therapeutics, Inc.	$1.95	-0.85×	0.56×	17.56×	-1.16×	-121.9%	-94.1%	-2222.4%	-2051.1%	-65.8%	-51.4%	-96.0%	0.38×	-0.25×	0×	5.79×	0.0%	3	-8.27	1	C-
IPSCCentury Therapeutics, Inc.	$1.81	-9.04×	0.54×	0.79×	19.64×	85.0%	88.0%	-13.8%	-8.8%	-6.0%	-7.2%	-121.6%	0.27×	-5.3×	0×	5.97×	0.0%	1	-1.94	2	C
NKTXNkarta, Inc.	$1.29	-1.31×	0.44×	0×	-1.83×	-132.8%	0.0%	0.0%	0.0%	-33.3%	-31.2%	-65.7%	0.24×	-0.39×	0×	12.69×	0.0%	1	-2.81	2	C
NTLAIntellia Therapeutics, Inc.	$11.85	-2.36×	1.45×	14.4×	-2.3×	-249.6%	76.5%	-651.7%	-609.9%	-61.5%	-57.7%	-36.4%	0.14×	0.16×	0×	5.08×	0.0%	4	2.17	2	C
Peer median	—	-1.31×	0.56×	4.49×	-1.16×	-132.8%	76.5%	-245.2%	-395.0%	-61.5%	-51.4%	-91.2%	0.27×	-0.25×	0×	5.79×	0.0%	3	-2.81	2	—